Compared with patients without KRT17 mutations, the overall survival (P = 2.582e-3), disease-specific (P = 9.757e-4), and progression-free (P = 7.266e-4) rates for ACC were lower for the KRT17 mutant group than for the non-mutant group (Figure 7). The gene discussed is KRT17; the disease is adrenal cortex carcinoma.